However, in the FLAURA trial, patients with a performance status (PS) of 0 to 1 were eligible, and the efficacy and safety of osimertinib treatment in patients with EGFR mutation-positive NSCLC with a poor PS (2 or more) have not been fully verified. This evidence concerns the gene EGFR and non-small cell lung carcinoma.